The impact of reduced dosing frequency of elranatamab on patient-reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-3.

ABSTRACT:

SUBMITTER: Bahlis NJ 

PROVIDER: S-EPMC12455012 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature